Customized mRNA Processing For Improved Therapy Development And Manufacturing

In vitro-transcribed mRNAs have shown great potential for various therapeutic applications, but their manufacturing comes with challenges. The complexity of these molecules, combined with the need to balance reagents in the reaction, presents difficulties in maintaining both potency and integrity. In vitro transcription (IVT) and capping reactions require a tailored approach rather than a standardized process. These reactions must be fine-tuned according to the individual molecule's composition, structure, and size to optimize mRNA development. Fine-tuning the process is essential for producing high-quality mRNAs that are critical for applications such as vaccines and other therapeutics.

In this presentation, Curia's Director of Process Development Scott Alderucci will explore new technologies and experimental design strategies for a customized approach to mRNA therapy development. He will cover key topics such as identifying critical components in mRNA production, revisiting procedures, and the importance of in-process analytics to ensure the development of effective mRNA therapies.